Trial Profile

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bicalutamide (Primary) ; Enzalutamide (Primary) ; Gonadotropin releasing hormone stimulants
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms STEEL

04 Jun 2024 Results assessing safety and efficacy of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation presented at the 60th Annual Meeting of the American Society of Clinical Oncology
27 Jan 2024 Initial results (n=188) presented at the 2024 Genitourinary Cancers Symposium.
01 Jun 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com